Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Supplementary Tables S1-3 and Figures S1-3. Table S1: Median, interquartile range (IQR), minimum (Min.) and maximum (max.) of follow-up time by cancer site. Table S2: Hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer risk according to circulating insulin-like growth factor-I concentrations. Table S3: Hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer risk according to circulating insulin-like growth factor-I concentrations stratified by follow-up time, sex and age-group. Figure S1: Flow diagram for reaching the analytical sample. Figure S2: Hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer risk per 5 nmol/l higher insulin-like growth factor-I concentration by cancer site and sex. Figure S3: Hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer risk per 5 nmol/l higher insulin-like growth factor-I concentration by cancer site and age (<55, {greater than or equal to}55 years) at biomarker assessment.</p>

Original publication

DOI

10.1158/0008-5472.22425544.v1

Type

Other

Publication Date

31/03/2023